A Phase II, Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-Center Study to Determine the Efficacy and Safety of TAK-379 in Subjects With Type 2 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Pioglitazone; TAK 379
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 31 Aug 2018 Biomarkers information updated
- 09 Jun 2010 Actual patient number (323) added as reported by ClinicalTrials.gov.
- 21 Apr 2009 Status changed from recruiting to discontinued, as reported in a Takeda media release.